% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Scuteri:163759,
author = {Scuteri, Damiana and Tonin, Paolo and Nicotera, Pierluigi
and Bagetta, Giacinto and Corasaniti, Maria Tiziana},
title = {{R}eal world considerations for newly approved {CGRP}
receptor antagonists in migraine care.},
journal = {Expert review of neurotherapeutics},
volume = {22},
number = {3},
issn = {1473-7175},
address = {Abingdon},
publisher = {Taylor $\&$ Francis Group},
reportid = {DZNE-2022-00498},
pages = {221 - 230},
year = {2022},
abstract = {Migraine is the leading cause of years lived with
disability in people under 50. Electrophysiological
phenomena at the basis of prodromal and headache attack
phases and of chronification processes involve
calcitonin-gene related peptide (CGRP) as a fundamental
player become a game changer of migraine pharmacotherapy.The
purpose of the present review is to retrace fundamental
stages of CGRP from its discovery to the role in migraine
pathogenesis and therapy to underscore the change of
paradigm offered by the newly approved small molecules to
antagonize CGRP receptor, the gepants. In particular, the
development of this new class is gone over from the initial
synthesis of C-terminus truncated CGRP antagonists to the
development of the first generation of gepants ending with
Zavegepant that can be considered the third generation.The
history of CGRP in migraine draws the successful road to
follow for key signaling pathways of modulation of
nociceptive facilitation by diencephalic and brainstem
nuclei, including dopaminergic neurotransmission, orexin A
and the large-conductance calcium-activated potassium (BKCa)
and ATP-sensitive potassium (KATP) channels also
investigating the potential of essential oils and the role
of polymorphisms. Real-world post marketing long-term data
are needed for gepants.},
subtyp = {Review Article},
keywords = {Calcitonin Gene-Related Peptide / Calcitonin Gene-Related
Peptide Receptor Antagonists: pharmacology / Calcitonin
Gene-Related Peptide Receptor Antagonists: therapeutic use /
Headache: drug therapy / Humans / Migraine Disorders: drug
therapy / Migraine Disorders: metabolism / Receptors,
Calcitonin Gene-Related Peptide / Atogepant (Other) / CGRP
antagonists (Other) / gepants (Other) / migraine (Other) /
rimegepant (Other) / ubrogepant (Other) / vazegepant (Other)
/ Calcitonin Gene-Related Peptide Receptor Antagonists (NLM
Chemicals) / Receptors, Calcitonin Gene-Related Peptide (NLM
Chemicals) / Calcitonin Gene-Related Peptide (NLM
Chemicals)},
cin = {AG Bano / Scientific board},
ddc = {610},
cid = {I:(DE-2719)1013003 / I:(DE-2719)1030000},
pnm = {351 - Brain Function (POF4-351)},
pid = {G:(DE-HGF)POF4-351},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:35240905},
doi = {10.1080/14737175.2022.2049758},
url = {https://pub.dzne.de/record/163759},
}